IMPORTANCE Prophylaxis and treatment guidelines for infective endocarditis have changed substantially over the past decade. In the United States, few population-based studies have explored the contemporary epidemiology and outcomes of endocarditis.
In the United States, recommendations for infective endocarditis prophylaxis underwent a major revision in 2007, incorporating a shift from routine antibiotic prophylaxis for patients with structural valve disease undergoing invasive procedures to prophylaxis restricted to patients undergoing specific dental procedures and with a history of valve replacement or repair, prior infective endocarditis, uncorrected congenital cyanotic heart lesions, or cardiac transplantation with valvulopathy. 10 The effect of these changes on the incidence and outcomes of endocarditis is unknown. The increased incidence and mortality of infective endocarditis reported in several analyses after the guideline changes 8,9,14 have not been confirmed by others. 2, 7, 15 To better define trends in the epidemiology and outcomes of infective endocarditis in the United States, this population-based study used mandatory databases tracking information on all patients across all hospitalizations in California and New York State from 1998 through 2013.
Methods

Study Design
Patients with infective endocarditis were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes in the Statewide Planning and Research Cooperative System database in New York and the Office of Statewide Health Planning and Development database in California. Both are all-payer, administrative databases that prospectively collect data on every hospital discharge, ambulatory surgery, and emergency department visit in their respective states. In these databases, each patient is allocated a unique identifier linking all encounters, permitting longitudinal analysis. Patients were included in the study if they had a first episode of infective endocarditis identified by either a primary or secondary diagnostic ICD-9-CM code 421.0, 421. 1, 421.9, 036.42, 098.84, 112.81, 115.04, 115.14, or 115.94 between January 1, 1998, and December 31, 2013 . Hospital admissions without a unique identifier as well as readmissions were excluded from the analysis (eFigure 1 in the Supplement).
Validation of ICD-9-CM coding for infective endocarditis, which preceded the final step of analytic data set creation, was performed using patients' electronic medical records identified from the Mount Sinai Data Warehouse. Hospitalizations with any possibility of infective endocarditis were identified either by keyword search ("endocarditis" or "vegetation") in any note from patients' medical records or by broader ICD-9-CM codes (421.0, 421.1, 421.9, 112.81, 036.42, 098.84, 115.04, 115.14, 115.94, 424.90, 424.91, and 424.99) in hospital inpatient discharge data at Mount Sinai Medical Center, New York, New York, from January 1, 2013 , through December 31, 2014 . We reviewed those hospitalizations (n = 1673), identified 515 hospitalizations and 283 patients with any type of infective endocarditis, and evaluated reliability of the ICD-9-CM codes for identification of infective endocarditis. The sensitivity, specificity, and positive predictive value of the ICD-9-CM codes for acute infective endocarditis defined by the modified Duke criteria 16 were 94% (95% CI, 92%-97%), 99% (95% CI, 99%-99%), and 94% (95% CI, 91%-97%), respectively (eTable 1A in the Supplement). To confirm generalizability of the positive predictive value in different hospital settings and different time frames, further code validation was conducted at 5 other facilities (4 urban settings and 1 rural setting; 2 academic medical centers [including 1 tertiary referral center] and 3 community hospitals) from January 1, 2013 , through December 31, 2014 , as well as hospitalizations at Mount Sinai Medical Center from January 1, 2003 , through December 31, 2005 (eTable 1B in the Supplement). Baseline comorbidities were identified using diagnosis and procedure codes from the index hospitalization and previous hospitalizations (eTable 2 in the Supplement).
This study was approved by the Data Protection Review Board of the New York State Department of Health, the Committee for the Protection of Human Subjects of the State of California, and the Program for Protection of Human Subjects at the Icahn School of Medicine, Mount Sinai Medical Center. The approval included a waiver of informed consent.
Definitions
Infective endocarditis was categorized based on disease types as native-valve endocarditis, prosthetic-valve endocarditis, cardiac device-related endocarditis, or drug abuserelated endocarditis. 12, 13 The ICD-9-CM codes and definitions used are listed in eTable 3 in the Supplement, and the hierarchical allocation algorithm is shown in eFigure 2A in the Supplement.
The mode of acquisition was categorized into nonhealth care-associated infective endocarditis (namely community-acquired infective endocarditis) or health careassociated infective endocarditis. Health care-associated infective endocarditis was further categorized into nosocomial or nonnosocomial infective endocarditis. The ICD-9-CM codes used are listed in eTable 4 in the Supplement, and the hierarchical allocation algorithm is shown in eFigure 2B in the Supplement. Nonnosocomial infective endocarditis was defined as infective endocarditis that was present on admission in patients with health care contact before the index hospitalization. Health care contact was identified as a history of receiving intravenous therapy (including chemotherapy), transfer from a specialized nursing care facility, hemodialysis, or hospitalization for 2 days or longer in the 90 days before the index admission.
17 Community-acquired infective endocarditis was defined as infective endocarditis that was present on admission in patients without prior health care contact. When patients were transferred from another hospital, they were classified as having nosocomial infective endocarditis if the length of stay in the previous admission was 2 days or longer; they were classified as having nonnosocomial infective endocarditis if their length of stay was shorter than 2 days and there was evidence of heath care contact before the first admission. 17 Nosocomial infective endocarditis was defined as infective endocarditis that was not present on admission if there was no transfer from another hospital. The study definitions of disease type and mode of acquisition were validated against medical records, with positive predictive values of 87% (95% CI, 81%-92%) and 83% (95% CI, 77%-89%), respectively. Causal microorganisms were identified using primary and secondary diagnostic codes within the limitation of ICD-9-CM, as follows: Staphylococcus aureus (including methicillin-resistant species), other Staphylococcus species, Streptococcus species, gram-negative bacilli, fungus, and unknown (which included culture-negative and uncoded cases). Among the entire cohort, 75% of patients had a causative microorganism coded. Specific ICD-9-CM codes do not exist for oral streptococci; therefore, ICD-9-CM codes primarily identifying nonpneumococcal, non-β-hemolytic, and nonenterococcal streptococci were used (eTable 5 in the Supplement). 15 The causal microorganisms identified in the state database were validated against medical records, with a positive predictive value of 88% (95% CI, 83%-94%). For oral streptococci, the positive predictive value was 84% (95% CI, 68%-100%).
Statistical Analysis
The crude incidence of infective endocarditis was calculated by dividing the number of patients with the first episodes of infective endocarditis in each year by the California and New York census populations in the same year, and it is reported per 100 000 persons. Direct standardization was used to account for changes in age, sex, and race in the California and New York population during the study period, using the population in 1998 as the reference. Multivariable Poisson regression analysis was performed to evaluate temporal trends in the incidence of infective endocarditis, adjusting for age, sex, and race. Trends in incidence were assessed by the annual percentage change (APC) with 95% confidence interval. Interrupted time series analysis was also performed using segmented regression 18 to assess the association with prevention guideline changes released in April 2007 and the incidence of infective endocarditis. Analyses were repeated with change points set at April 2007 , October 2007 , and April 2008 for the possible time lag of guideline change to be effective in practice and also excluding data during 6-month or 1-year lag periods. 18 Crude incidence trend, direct standardization, multivariable Poisson regression, and interrupted time series analysis with segmented regression analyses were all performed for both all infective endocarditis cases and oral streptococcal infective endocarditis cases. For descriptive analysis, continuous variables are reported as means with standard deviations, and categorical variables are expressed as proportions per the total number of infective endocarditis cases. Trends in patient age were evaluated with the ordinary least squares method, and trends in proportion are presented as APC with 95% confidence interval. Log-linear Poisson regression was used to estimate the APC where the offset was a logarithm of the denominator. To evaluate the trend in 90-day mortality during the study period and predictors of 5-year mortality, multivariable Cox regression was performed, adjusting for age, sex, race, baseline comorbidities (hypertension, diabetes, chronic kidney disease, coronary artery disease, peripheral vascular disease, chronic obstructive pulmonary disease, liver disease, history of malignancy, and history of congenital heart disease), disease types, acquisition mode, organism, and admission year. For 90-day and 5-year mortality, the study cohort from January 1, 1998, through December 31, 2011, was used. Survival curves were drawn using the Kaplan-Meier method and compared using the log-rank test with Sidak adjustment for multiple comparisons. Deaths in New York were ascertained using a full Social Security Death Master File (last follow-up was May 29, 2015) as well as deceased discharge disposition at the subsequent inpatient and emergency department visits. Deaths in California were ascertained from linked vital statistics data (last available follow-up was December 31, 2011).
There were no missing values for age, sex, race, admission dates, or discharge dates. The 2% of the study cohort for whom race was categorized as unknown were included in the category of other. To evaluate generalizability of the results to the entire US population, the demographic characteristics and baseline comorbidities of patients with infective endocarditis identified in the Nationwide Inpatient Sample were compared between the California and New York population and the entire US population (eAppendix in the Supplement). Additionally, a sensitivity analysis was conducted to assess consistency of the findings across different geographical locations in the United States. Analyses for trends in incidence and 90-day mortality were repeated stratified by state (sensitivity analysis for 90-day mortality had a different last follow-up in each state). All tests were 2-tailed, and an α level of .05 was considered statistically significant. All statistical
Results
Incidence
Between January 1, 1998, and December 31, 2013, 75 A total of 7748 patients (10.2%) were transferred from another hospital. The crude incidence increased from 7.6 to 9.3 cases per 100 000 persons annually (APC, 1.1%; 95% CI, 0.8% to 1.4%; unadjusted Poisson regression P < .001) (eFigure 3A in the Supplement; crude incidence stratified by age, sex, and race is shown in eFigure 3B-D in the Supplement). The incidence was significantly higher in male, nonwhite, and elderly patients (eFigure 4 in the Supplement). After adjusting for age, sex, and race, there was no significant increase in the incidence of endocarditis over time (range, 7.6 [95% CI, 7.4 to 7.9 ] to 7.8 [95% CI, 7.6 to 8.0] cases per 100 000 persons annually; APC, −0.06%; 95% CI, −0.3% to 0.2%; multivariable Poisson regression P = .59) (Figure 1) . Segmented regression did not show an increase in slope of incidence after the guideline changes (eFigure 5A and eTable 6 in the Supplement). A sensitivity analysis was conducted in each state and confirmed no significant increase in the standardized incidence or in the slope of incidence after the guideline changes (eFigure 5B and C and eFigure 6 in the Supplement).
Patient Characteristics
Patient characteristics in California and New York were similar to those of the entire US population (eTable 7 in the Supplement). Patients diagnosed with infective endocarditis in the latter part of the study period were older, more likely to be male, and more likely to have chronic obstructive pulmonary disease, cancer, and liver disease compared with patients in the earlier part of the study period (Table) . From 1998 through 2013 among the patients with endocarditis, the proportion of patients with a history of valve surgery increased from 12.8% to 15.2% (APC, 1.6%; 95% CI, 1.2% to 2.0%; P < .001), and the proportion of patients with implanted pacemakers or defibrillators increased from 8.8% to 15.6% (APC, 4.8%; 95% CI, 4.3% to 5.2%; P < .001). As a result, the proportion of patients with native-valve endocarditis decreased from 74.5% to 68.4% (APC, −0.7%; 95% CI, −0 . 9%to−0 .5 %;P < .001), whereas prosthetic-valve endocarditis increased from 12.0% to 13.8% (APC, 1.3%; 95% CI, 0.8% to 1.7%; P < .001) and cardiac device-related endocarditis increased from 1.3% to 4.1% (APC, 8.8%; 95% CI, 7.8% to 9.9%; P < .001) (Table) .
Mode of Acquisition and Pathogens
The proportion of health care-associated infective endocarditis accounted for nearly half of all infective endocarditis cases during the study period, with 49.8% in 1998 through 2001 and 51.2% in 2010 through 2013 (APC, 0.2%; 95% CI, −0.04% to 0.4%; P = .10). The proportion of patients with health care-associated nonnosocomial infective endocarditis among all patients with endocarditis increased from 32.1% to 35.9% (APC, 0.8%; 95% CI, 0.5% to 1.1%; P < .001), and health care-associated nosocomial infective endocarditis decreased from 17.7% to 15.3% (APC, −1.0%; 95% CI, −1.4% to −0.7%; P < .001). The proportion of patients who were dependent on dialysis increased by 38.3% (95% CI, 23.7% to 54.6%) from 14.9% to 17.9% (APC, 1.0%; 95% CI, 0.6% to 1.3%; P < .001), accounting for 35.0% of health careassociated infective endocarditis cases in 2010 through 2013 (Table) .
The standardized incidence of infective endocarditis caused by S aureus increased from 2.1 (95% CI, 2.0 to 2.2) to 2.7 (95% CI, 2.6 to 2.9) cases per 100 000 persons annually during the study period (APC, 1.0%; 95% CI, 0.6% to 1.4%; P < .001), and the standardized incidence of infective endocarditis among patients with methicillin-resistant S aureus All infective endocarditis
Oral streptococcal endocarditis
Direct standardization was performed to account for changes in age, sex, and race in the California and New York State census population during the study period, using the population in 1998 as the reference. For all infective endocarditis cases, the annual percentage change was −0.06% (95% CI, −0.3% to 0.2%; P = .59); for oral streptococcal endocarditis cases, the annual percentage change was −1.3% (95% CI, −1.8% to −0.7%; P < .001). P values were calculated using multivariable Poisson regression and were 2-tailed. The shaded regions indicate 95% confidence intervals.
Supplement). The crude incidence of patients diagnosed with oral streptococcal infective endocarditis did not change (from 0.84 to 0.88 cases per 100 000 persons annually; a P values were calculated using 2-tailed log-linear Poisson regression.
b P values was calculated using the ordinary least squares method. APC, −0.1%; 95% CI, −0.8% to 0.6%; unadjusted Poisson regression P = .77) (eFigure 3A in the Supplement). After adjusting for age, sex, and race, the incidence decreased over time (from 0.84 [95% CI, 0.76 to 0.92] to 0.73 [95% CI, 0.67 to 0.80] cases per 100 000 persons annually; APC, −1.3%; 95% CI, −1.8% to −0.7%; multivariable Poisson regression P < .001) (Figure 1 ). Segmented regression did not show an increase in the slope of incidence of oral streptococcal infective endocarditis after the guideline changes (eFigure 5A and eTable 6 in the Supplement). Sensitivity analysis was conducted in each state and confirmed no significant increase in the standardized incidence of oral streptococcal infective endocarditis or in the slope of its incidence after the guideline change (eFigure 5B and C and eFigure 6 in the Supplement).
Mortality
Crude 90-day mortality was unchanged from 1998 through 2011 (from 23.9% to 24.2%, respectively; APC, −0.3%; 95% CI, −1.0% to 0.4%; P = .44). After risk adjustment for patient demographic characteristics and comorbidities, the risk of mortality decreased 2% per year over time (adjusted hazard ratio per year, 0.982; 95% CI, 0.978 to 0.986; P < .001). The proportion of patients who underwent cardiac surgery during or within 30 days of their index admission increased during the study period from 10.6% to 13.3% (APC, 2.2%; 95% CI, 0.8% to 3.6%; P < .001). Sensitivity analysis confirmed a decreased adjusted risk of 90-day mortality during the study period in each state. In California, crude 90-day mortality was 23.4% in 1998 and 23.6% in 2011 (APC, 0.3%; 95% CI, −0.5% to 1.1%; adjusted hazard ratio per year, 0.985; 95% CI, 0.980 to 0.990; P < .001). In New York, crude 90-day mortality was 24.4% in 1998 and 24.1% in 2013 (APC, −0.3%; 95% CI, −1.0% to 0.4%; adjusted hazard ratio per year, 0.978; 95% CI, 0.973 to 0.983; P < .001).
Overall mortality at 1 year and 5 years was 37.1% (95% CI, 36.8%-37.5%) and 52.9% (95% CI, 52.5%-53.3%), respectively. Health care-associated infective endocarditis was associated with significantly higher mortality than community-acquired endocarditis (adjusted hazard ratio, 1.52; 95% CI, 1.48-1.56; P < .001) (Figure 2) . Figure 3 depicts survival stratified by pathogen. Compared with streptococcal infections, mortality was higher for gram-negative infections (adjusted hazard ratio, 1.22; 95% CI, 1.16-1.28; P < .001), staphylococcal infections (adjusted hazard ratio, 1.38; 95% CI, 1.34-1.42; P < .001), and fungal infections (adjusted hazard ratio, 1.84; 95% CI, 1.72-1.99; P < .001).
Discussion
In this retrospective cohort study of 75 829 inpatients with a first episode of infective endocarditis in California and New York from 1998 through 2013, the standardized incidence remained stable between 7.6 and 7.8 cases per 100 000 persons, and the adjusted hazard ratio of 90-day mortality decreased approximately 2% per year. There were shifts in patterns of patient characteristics and etiology, with increases in the proportion of prosthetic-and device-related endocarditis and in health care-associated nonnosocomial endocarditis, decreases in the proportion of native-valve endocarditis and in health care-associated nosocomial endocarditis, and no increase in the incidence of oral streptococcal endocarditis. To our knowledge, this study is the first to report population trends in standardized incidence of de novo endocarditis in a US population; to report trends in mortality, surgical treatment, and long-term outcomes; and to report shifts in modes of acquisition and pathogens, including nosocomial infections and high-risk groups, such as patients receiving dialysis. The study period spanned changes in prevention of infective endocarditis. The American Heart Association revised the consensus guidelines for antibiotic prophylaxis of infective endocarditis in 2007, recommending much more restrictive use of antibiotic prophylaxis. The main changes were removal of the recommendations for routine antibiotic prophylaxis for invasive dental procedures in low-and moderate-risk patients and for most other invasive procedures in all patients.
10 A substantial decrease in prescribing antibiotic prophylaxis following revised consensus guidelines occurred in the United Kingdom, 14 and regional survey data suggest that prescribing patterns were similarly affected in the United States. 15, 19 In Canada, a 45% decrease in antibiotic prophylaxis recommendations for low-risk patients and a 10% decrease for high-risk patients were reported.
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The overall standardized incidence of infective endocarditis appeared to remain stable, which was contrary to previous studies. 9,14 This may be because previous studies reported the crude incidence of endocarditis without adjusting for changing population mix, because they analyzed first episodes and recurrent infective endocarditis together (resulting in overestimates of the incidence of infective endocarditis), or because of the trend analysis methods used. [21] [22] [23] These data supported findings of a much smaller county-based study 2 and of a Medicare database 7 in a large sample more representative of the US population and suggested that the recommendations restricting antibiotic prophylaxis for dental procedures had not contributed to increased oral streptococcal endocarditis. 15 This study highlights the emergence of infective endocarditis unlikely to be associated with dental procedures, such as staphylococcal or health care-associated endocarditis. Health care-associated endocarditis accounted for more than 50% of native-valve endocarditis and was associated with 50% mortality at 1 year. Nonnosocomial health careassociated endocarditis (ie, infections likely acquired through outpatient health care) increased steadily across the study period, whereas nosocomial endocarditis cases declined during this period. This decrease coincided with coordinated efforts to reduce hospital-acquired infections through evidencebased consensus guidelines, bundled interventions, and public reporting. 24, 25 Prospective studies are needed to assess whether these approaches could and should be applied to outpatient care.
The mortality rate associated with de novo endocarditis remained high along with the increase in resistant pathogens and patient morbidity, with marginal improvement in adjusted mortality risk. The excess mortality observed with health care-associated endocarditis compared with communityacquired endocarditis underscores the importance of efforts focused on reducing the occurrence of preventable health careacquired infection. Given the limits of available therapeutic interventions, it is likely that any further improvements in the outcomes of endocarditis will take place in small increments. Consequently, more effective prevention of health careassociated endocarditis may achieve the greatest reductions in the burden of this disease.
The main strengths of this study were the population data drawn from mandatory, all-comer state data sets allowing comprehensive identification and follow-up of all patients diagnosed with infective endocarditis in California and New York, representing 18.6% of the US population during the study period. This study demonstrated that this large patient population was representative of the overall population of patients hospitalized with endocarditis in the United States (eTable 7 in the Supplement). Used in conjunction with state census data, these data sets permitted accurate estimates of standardized infective endocarditis incidence and changes in the risk profile of the population, providing a more informed analysis of trends than crude incidence in isolation. The ability to follow patients up longitudinally provided new insights into the evolving etiology Patients admitted from 1998 through 2011 were included in the analysis for long-term outcomes. Staphylococcus and Streptococcus each include the entire genus. , 1998-2013 of infective endocarditis, particularly nonnosocomial infection. The lower proportion of patients who underwent valve surgery in the present cohort compared with those reported in previous prospective cohort studies is likely explained by the more broadly representative nature of the sample of the present study in contrast with the highly selected populations seen by cardiac surgery programs. 5 Additionally, previous studies either were performed using data sets that did not permit accurate longitudinal follow-up and consequently conflated de novo endocarditis cases with recurrences, relapses, and transferred cases, 6,9 or consisted of US patient populations that were too small or not representative of the general population. 2, 7, 15 The use of single trend testing and less specific ICD-9-CM codes may undermine the validity of observed trends in endocarditis and their association with guideline changes.
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Limitations
This study has several limitations related to the use of administrative data sets, which may be subject to inaccurate coding of patient clinical diagnoses and procedures, with clinical information limited to conditions and treatments defined by ICD-9-CM codes. Consequently, the changes we observed and the long-term outcomes may have been affected by unmeasured confounders. However, validation of ICD-9-CM codes was performed using clinical records in a subset of patients with high positive predictive values. There were no ICD-9-CM codes to identify skilled home nursing care and wound care, which are normally included in the definition of health care-associated infection; consequently, the number of health care-associated infections could have been underestimated. It was not possible to identify the date when blood cultures were performed during hospitalization, and it was therefore assumed that patients who had a diagnosis of infective endocarditis on admission had either nonnosocomial or community-acquired endocarditis based on health care contact prior to admission. The organisms identified by ICD-9-CM codes were assumed to be causative if they were coded during the hospitalizations with infective endocarditis, but this could not be validated for individual patients. It was also not possible to differentiate between culture-negative infective endocarditis and infective endocarditis for which the causative organism was simply not recorded. Oral streptococcal endocarditis was defined by exclusion, so despite high positive predictive value, this may still be subject to misclassification; without additional information on dental procedures and concurrent antibiotic prophylaxis, our data did not confirm that the organisms were indeed of oral origin and did not confirm the role of dental prophylaxis in incidence. Microbiological etiology was unknown or not specified in 23% to 27% of cases, allowing a margin for error. Patients who recently moved from different states or different countries may not have had previous admissions in the database, which would lead to an underestimate of baseline comorbidities and the incidence of nonnosocomial infections. Additionally, the most recent data were 4 years old, and the study findings may not reflect the current characteristics and outcomes associated with infective endocarditis.
Conclusions
In California and New York State, the overall standardized incidence of infective endocarditis did not increase from 1998 through 2013, with changes in patient characteristics and etiology over this time.
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6B) New York State
Direct standardization performed to account for changes in age, sex, and race in the California and New York State census population over the study period, using the population in 1998 as the reference. P values were calculated using multivariable Poisson regression. The shaded regions indicate 95% confidence intervals. 
7B) Standardized Incidence
Direct standardization performed to account for changes in age, sex, and race in the California and New York State census population over the study period, using the population in 1998 as the reference. P values were calculated using multivariable Poisson regression. Hospitalizations with any possibility of infective endocarditis were identified by key words (endocarditis or vegetation) in any note included in patients' medical records or broader ICD-9 codes (421.0, 421.1, 421.9, 112.81, 036.42, 098.84, 115.04, 115.14, 115.94, 424.90, 424.91 and 424.99) in hospital inpatient discharge data at Mount Sinai Medical Center between 2013 and 2014. We reviewed those hospitalizations (n=1673) and identified 515 hospitalizations and 283 patients with any types of infective endocarditis. Specifically, infectious disease specialists' documentations, echocardiographic image results, blood culture results, and operative reports were reviewed. True positives were identified as cases where both medical charts and ICD9 coding were concordant, false negatives were cases identified from medical charts only, false positives were cases identified from ICD9 codes only, and true negatives were cases without endocarditis in either medical charts or discharge database, which was calculated by deducting the number of endocarditis hospitalizations from the total number of hospitalizations at Mount Sinai Medical Center for 2013-2014 (n=114,825) . We evaluated reliability of the ICD-9 codes used to identify definite IE and possible IE defined in modified Duke criteria.
The ICD-9 codes we used to identify active infective endocarditis for the final analytic dataset were primary and secondary diagnosis of 421.0, 421.1, 421.9, 112.81, 036.42, 098.84, 115.04, 115.14 401, 4010, 4011, 4019, 402, 4020, 40200, 40201, 4021, 40210, 40211, 4029, 40290, 40291, 403, 4030, 40300, 40301, 4031, 40310, 40311, 4039, 40390, 40391, 404, 4040, 40400, 40401, 40402, 40403, 4041, 40410, 40411, 40412, 40413, 4049, 40490, 40491, 40492, 40493, 405, 4050, 40501, 40509, 4051, 40511, 40519, 4059, 40591, 40599 and 4372 Complicated diabetes Diagnosis codes (index or prior admissions) 2504, 25040, 25041, 25042, 25043, 2505, 25050, 25051, 25052, 25053, 2506, 25060, 25061, 25062, 25063, 2507, 25070, 25071, 25072, 25073, 2509, 25090, 25091, 25092 and 25093 Coronary artery disease Diagnosis codes (index or prior admissions) 410, 4100, 41000, 41001, 41002, 4101, 41010, 41011, 41012, 4012, 40120, 41021, 41022, 4103, 41030, 41031, 41032, 4104, 41040, 41041, 41042, 4105, 41050, 41051, 41052, 4106, 41060, 41061, 41062, 4107, 41070, 41071, 41072, 4108, 41080, 41081, 41082, 4109, 41090, 41091, 41092, 411, 4110, 4111, 4118, 41181, 41189, 412, 413, 4130, 4131, 4139, 414, 4140, 41400, 41401, 41402, 41403, 41404, 41405, 41406, 41407, 4142, 4143, 4144, 4295, 4296, 4297, 42971, 42979, V4581 and V4582 Procedure codes (prior admissions) 361, 3610, 3611, 3612, 3613, 3614, 3615, 3616, 3617, 3619, 0066, 1755, 3601, 3602, 3603, 3604, 3605, 3606, 3607, 3608 and 3609 Peripheral vascular disease Diagnosis codes (index or prior admissions) 4400, 4401, 4402, 44020, 44021, 44022, 44023, 44024, 44029, 4403, 44030, 44031, 44032, 4404, 4408, 4409, 4471, 9961, 99662, 99674 and V434 Chronic obstructive pulmonary disease Diagnosis codes (index or prior admissions) 491, 4910, 4911, 4912, 49120, 49121, 49122, 4918, 4919, 492, 4920, 4928, 493, 4930, 49300, 49301, 49302, 4931, 49310, 49311, 49312, 4932, 49320, 49321, 49322, 4938, 49380, 49381, 49382, 4939, 49390, 49391, 49392, 494, 4940, 4941 and 496 Chronic kidney disease Diagnosis codes (index or prior admissions) 403, 4030, 40300, 40301, 4031, 40310, 40311, 4039, 40390, 40391, 404, 4040, 40400, 40401, 40402, 40403, 4041, 40410, 40411, 40412, 40413, 4049, 40490, 40491, 40492, 40493, 585, 5851, 5852, 5853, 5854, 5855, 5859, a ICD-9 CM codes 586, V420, V56, V560, V561, V562, V563, V5631, V5632, V568, 5856, V451, V4511 and V4512 Liver disease Diagnosis codes (index or prior admissions) 070, 0700, 0701, 0702, 07020, 07021, 07022, 07023, 0703, 07030, 07031, 07032, 07033, 0704, 07041, 07042, 07043, 07044, 07049, 0705, 07051, 07052, 07053, 07054, 07059, 0706, 0707, 07070, 07071, 0709, 456, 4560, 4561, 4562, 45620, 45621, 4563, 4564, 4565, 4566, 4568, 570, 571, 5710, 5711, 5712, 5713, 5714, 57140, 57141, 57142, 57149, 5715, 5716, 5718, 5719, 572, 5720, 5721, 5722, 5723, 5724, 5728, 573, 5730, 5731, 5732, 5733, 5734, 5735, 5738, 5738, 7824, 7891, 7895, 78951, 78959, 7904, 7905, 7948 and V427 Cancer Oropharyngeal cancers Diagnosis codes (index or prior admissions) 140, 1400, 1401, 1403, 1404, 1405, 1406, 1408, 1409, 141, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1418, 1419, 142, 1420, 1421, 1422, 1428, 1429, 143,1430, 1431, 1438, 1439, 144, 1440, 1441, 1448, 1449, 145, 1450, 1451, 1452,1453, 1454, 1455, 1456, 1458, 1459, 146, 1460, 1461, 1462, 1463, 1464, 1465,1466, 1467, 1468, 1469, 147, 1470, 1471, 1472, 1473, 1478, 1479, 148, 1480,1481, 1482, 1483, 1488, 1489, 149, 1490, 1491, 1498 and 1499 Gastrointestinal cancers Diagnosis codes (index or prior admissions) 150, 1500, 1501, 1502, 1503, 1504, 1505, 1506, 1508, 1509, 1510, 151, 1511, 15012, 1513, 1514, 1515, 1516, 1518, 1519, 152, 1520, 1521, 1522, 1523, 1528, 1529, 153, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538, 1539, 154,1540, 1541, 1542, 1543, 1548, 155, 1550, 1551, 1552, 156, 1560, 1561, 1562, 1568, 1569, 157, 1570, 1571, 1572, 1573, 1574, 1578, 1579, 158, 1580, 1588,1589, 159, 1590, 1591, 1598 and 1599 Respiratory tract cancers Diagnosis codes (index or prior admissions) 160, 1600, 1601, 1602, 1603, 1604, 1605, 1608, 1609, 161, 1610, 1611, 1612, 1613, 1618, 1619, 162, 1620, 1622, 1623, 1624, 1625, 1628, 1629, 163, 1630, 1631, 1638, 1639, 164, 1640, 1461, 1462, 1463, 1468, 1649, 165, 1650, 1658, and 1659 Bone and connective tissue cancer Diagnosis codes (index or prior admissions) eTable 3. ICD-9 Codes for Disease Types ICD-9 CM codes History of drug abuse Diagnosis code (index or prior admissions) 304, 3040, 3041, 3042, 3043, 3044, 3045, 3046, 3047, 3048, 3049, 30400, 30401, 30402, 30403, 30410, 30411, 30412, 30413, 30420, 30421, 30422, 30423, 30430, 30431, 30432, 30433, 30440, 30441, 30442, 30443, 30450, 30451, 30452, 30453, 30460, 30461, 30462, 30463, 30470, 30471, 30472, 30473, 30480, 30481, 30482, 30483, 30490, 30491, 30492, 30493, 305, 3052, 3053, 3054, 3055, 3056, 3057, 3058, 3059, 30520, 30521, 30522, 30523, 30530, 30531, 30532, 30533, 30540, 30541, 30542, 30543, 30550, 30551, 30552, 30553, 30560, 30561, 30562, 30563, 30570, 30571, 30572, 30573, 30580, 30581, 30582, 30583, 30590, 30591, 30592, 30593, 9650, 96500, 96501, 96502 3770, 3771, 3772, 3773, 3774, 3775, 3776, 3780, 3781, 3782, 3783, 3785, 3786, 3787, 3794, 3795, 3796, 3797, 3798, 0050, 0051, 0053 
eAppendix. Supplemental Methods
The patients in California and New York State appear typical of patients in the rest of the US in terms of demographics and underlying disease (eTable 7). In order to compare patient characteristics across the US we used the Nationwide Inpatient Sample (NIS), because this provides information from patient episodes sampled from all states (the dataset we employed for the present study is limited to California and New York State).
The NIS is a database developed for the Healthcare Cost and Utilization Project. The NIS samples hospitalizations at 20% of hospitals from participating states and 100% of hospitalizations from these hospitals using methodology designed to provide a representative cross-section of United States hospitalizations. The NIS includes ICD-9-CM diagnosis codes, but does not distinguish between conditions that were present on admission, or acquired during the hospitalization. The NIS does not include unique patient identifiers, and so longitudinal tracking of patients before and after the index hospital admission is not possible.
The time frame of 2005 and 2011 was chosen to avoid significant sampling change. The same ICD-9-CM codes in the present study were used to identify hospitalizations with diagnosis of infective endocarditis and comorbidities and causative pathogen from primary and secondary diagnosis codes. Continuous variables were reported as mean and standard deviation. Categorical variables were reported as numbers and proportions. Difference was reported by standardized difference.
The most prominent differences between characteristics of endocarditis patients in California and New York State compared to the whole US, were seen with regards to non-White and non-Black race -this is primarily because of the variability in completeness of coding for race in the NIS. These limitations of the Nationwide Inpatient Sample do not affect the data used in the present study.
In summary, for the variables we were able to compare, patients admitted with endocarditis in California and New York State are typical of patients in the entire US.
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